Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial
2017 ◽
Vol 18
(6)
◽
pp. 743-754
◽
Keyword(s):
Phase 3
◽
2018 ◽
Vol 48
(9)
◽
pp. 855-859
◽
Keyword(s):
2011 ◽